The scope of the report is to highlight and gauge existing technologies in the production of therapeutic mAbs. The report also discusses key insights on interchangeability and substitution of therapeutic antibodies and biosimilars.
Further, there is also an assessment of the current drivers and restraints that affect the uptake of biosimilars.
The report answers key questions that are paramount for understanding the ... Read more